Global Recombinant Hirudin Medicine Market Size, Share and Trends Analysis Report, By Type (12000 ATU/mg, 16000 ATU/mg, Others), By Application (Thrombosis Disease, Tumor Disease, Others), Forecast (2022-2028)

The global recombinant hirudin medicinemarket is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Recombinant hirudin is a potent thrombin inhibitor originally found in the therapeutic leech. The recombinant hirudin drugs market is driven by factors such as an increase in the number of patients suffering from trauma and an increasing number of thrombin-based diseases. Additionally, a growing number of emerging economic health care facilities are likely to provide growth opportunities for market players. It is a potent and direct inhibitor of thrombin and has been shown to inhibit the growth and metastasis of several types of cancer in tumor test models.

The plant-derived thrombin (chronic thrombin) is investigated for tumor growth and metastasis testing in mice using hirudin, a special potent inhibitor of thrombin. Pre-treatment with hirudin prevented implantation in nude or syngeneic mice, followed by less than 2 human injections and 2 murine tumors. Hirudin created a slower duration of tumor growth, compared with phosphate-buffered saline treatment, but did not contribute to tumor growth in vivo or in vitro tumor growth. Hirudin treatment-induced central necrosis of the tumor module compared with no effect on PBS treatment. Extensive protection has been noted over the long course of treatment. Tumor growth in the blood was assessed with green fluorescent protein labeled tumor cells. Thus, chronic thrombin contributes to tumor transplantation, germination, and spontaneous metastasis. The powerful antithrombin agent should be clinically beneficial for cancer patients.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Abbott, Bioassay Technology Laboratory, Novus Biologicals, Pfizer Inc., Teva Pharmaceutical Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Recombinant Hirudin Medicine Market Report by Segment

By Type

• 12000 ATU/mg
• 16000 ATU/ mg
• Others

By Application

• Thrombosis Disease
• Tumor Disease
• Others

Global Recombinant Hirudin Medicine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa